Drug Forecasting Service Adds Thought Leader Input

In the US, Sagient Research Systems has added the Thought Leader Opinions (TLO) service to its pharma and biotech analytics tool BioMedTracker, to provide subscribers with direct access to expert opinion on specific disease areas.

Sagient publishes specialized research and data, and develops, produces and sells proprietary research products globally. Its BioMedTracker offers proprietary clinical assessments and patient-based revenue forecasts for developmental drugs, also advising on the likelihood of their approval.

The firm's new TLO service provides subscribers with access to more than 700 recent interviews from 300 medical/clinical 'thought leaders' - across 30 practice specialisms and 90 indications.

These interviews provide analysis of issues such as whether a late stage drug will be approved by the FDA, whether that drug's approval will affect current prescription practice, and what market implications the recent results of a trial will have.

It also offers opinion on how recent safety concerns will affect how a doctor prescribes a particular drug, or how the pricing of a new medicine will impact its uptake in the market.

'Understanding what experts think about drugs in development before they reach the advisory panel has never been more important,' states Robert Kyle, CEO of Sagient Research. 'We launched the TLO service to help clients better predict the approvability and future market potential of the drugs that they follow.'

Web sites: www.sagientresearch.com and www.biomedtracker.com .